Can PPARγ agonists have a role in the management of obesity-related hypertension?

Vascular Pharmacology

Volumn 45, Issue 1, 2006, Pages 46-53

  Chetty, Vasudhevan T ^a   Sharma, Arya M ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Hypertension; Obesity; Peroxisome proliferator activated receptor; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALACEPRIL; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOSE TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTERY INTIMA PROLIFERATION; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENDOTHELIUM CELL; ENDOTHELIUM LESION; GENETIC TRANSCRIPTION; GLUCOSE HOMEOSTASIS; HEART; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY; LIGAND BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SMOOTH MUSCLE FIBER; SODIUM RETENTION; SPLEEN; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE; ANIMAL; CONTROLLED CLINICAL TRIAL; DRUG POTENTIATION; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; OBESITY; PPAR GAMMA; RANDOMIZED CONTROLLED TRIALS; THIAZOLIDINEDIONES;

EID: 33745495558     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2005.11.010     Document Type: Review

References (78)

1. Altshuler D., Hirschhorn J.N., Klannemark M., et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat. Genet. 26 (2000) 76-80
2. Amb Sarafidis P.A., Lasaridis A.N., Nilsson P.M., Pagkalos E.M., Hitoglou-Makedou A.D., Pliakos C.I., Kazakos K.A., Yovos J.G., Zebekakis P.E., Tziolas I.M., and Tourkantonis A.N. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J. Hypertens. 22 (2004) 1769-1777
3. Anderson E.A., and Mark A.L. The vasodilator action of insulin: implications for the insulin hypothesis of hypertension. Hypertension 21 (1993) 136-141
4. Andrews H.E., Brackdorfer K.R., Dunn R.C., and Jacobs M. Low density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature 327 (1987) 237-239
5. Bakris G., Viberti G., Weston W.M., Heise M., Porter L.E., and Freed M.I. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J. Hum. Hypertens. 17 (2003) 5-6
6. Barroso I., Gurnell M., Crowley V.E., et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus, and hypertension. Nature 402 (1999) 880-883
7. Barton M., and d'Uscio L.V. Hypertension, diabetes mellitus, hypercholesterolemia, and endothelin B receptor-mediated renal nitric oxide release. Circulation 13 101 (2000) E228-E229
8. Brands M.W., and Hopkins T.E. Poor glycemic control induces hypertension in diabetes mellitus. Hypertension 27 part 2 (1996) 735-739
9. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., Scott S., Rude R.K., and Hseuh W.A. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J. Clin. Invest. 96 (1995) 354-360
10. Chen S., Noguchi Y., Izumida T., Tatebe J., and Katayama S. A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone. J. Hypertens. 14 (1996) 1325-1330
11. Chopra M., Galbraith S., and Darnton-Hill I. A global response to a global problem: the epidemic of overnutrition. Bull. World Health Organ. 80 (2002) 952-958
12. Collingwood T.N., Urnov F.D., and Wolffe A.P. Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J. Mol. Endocrinol. 23 (1999) 255-275
13. Creager M.A., Cooke J.P., Mendelsohn M.E., Gallagher S.J., Coleman S.M., Loscalzo J., and Dzau V. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J. Clin. Invest. 86 (1990) 228-234
14. Da Ros R., Assaloni R., and Ceriello. The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet. Med. 21 (2004) 1249-1252
15. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 334 (1996) 952-957
16. Desvergne B., and Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20 (1999) 649-688
17. Diep Q.N., El Mabrouk M., Cohn J.S., Endemann D., Amiri F., Virdis A., Neves M.F., and Schiffrin E.L. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 14 105 (2002) 2296-2302
18. Dobrian A.D., Schriver S.D., Khraibi A.A., and Prewitt R.L. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43 (2004) 48-56
19. Draznin B., Sussman K.E., Eckel R.H., Kao M., Yost T., and Sherman N.A. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J. Clin. Invest. 82 (1988) 1848-1852
20. Dubey R.K., Zhang H.Y., Reddy S.R., Boegehold M.A., and Kotchen T.A. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. 265 (1993) R726-R732
21. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
22. Fasshauer M., Klein J., Neumann S., Eszlinger M., and Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 507 (2001) 142-146
23. Ferrannini E., Buzzigoli R., Bonadonna R., et al. Insulin resistance in essential hypertension. N. Engl. J. Med. 26 (1987) 350
24. Fujiwara K., Hayashi K., Ozawa Y., Tokuyama H., Nakamura A., and Saruta T. Renal protective effect of troglitazone in Wistar fatty rats. Metabolism 49 (2000) 361-364
25. Fullert S., Schneider F., Haak E., Rau H., Badenhoop K., Lubben G., Usadel K.H., and Konrad T. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 87 (2002) 5503-5566
26. Gearing K.L., Gottlicher M., Teboul M., Widmark E., and Gustafsson J.A. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 1440-1444
27. Ghazzi M.N., Perez J., Antonucci T.K., Driscoll J.H., Huang S.M., Faja B.W., and Whitcomb R.W. Cardiac and glycaemic benefits of troglitazone treatment in NIDDM. Diabetes 46 (1997) 433-439
28. Grinsell J.W., Lardinois C.K., Swislocki A., Gonzalez R., Sare J.S., and Starich G.H. Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat. Am. J. Hypertens. (2000) 13370-13375
29. Hall J.E. The kidney, hypertension, and obesity. Hypertension 41 (2003) 625-633
30. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., Fu Y., Motone M., Yamamoto K., Matsuo A., Ohashi K., Kihara S., Funahashi T., Rakugi H., Matsuzawa Y., and Ogihara T. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 43 (2004) 1318-1323
31. Jones B.H., Standridge M.K., Taylor J.W., and Moustaid N. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am. J. Physiol. 273 (1997) R236-R242
32. Katayama Shigerhiro, Mari Abe, Hideyuki Kashiwabara, Itaru Kosegawa, Jun Ishii, June 2004. Evidence Against a Role of Insulin in Hypertension in Spontaneously Hypertensive Rats. CS-045 Does Not Lower Blood Pressure Despite Improvement of Insulin Resistance. Hypertension 23,1071-1074.
33. Kaufman L.N., Peterson M.M., and DeGrange L.M. Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 44 (1995) 1105-1109
34. Kawano Y., Okuda N., Minami J., Takishita S., and Omae T. Effects of a low-energy diet and an insulin-sensitizing agent on ambulatory blood pressure in overweight hypertensive patients. J. Hypertens. 18 (2000) 1451-1455
35. Koh-Banerjee P., Wang Y., Hu F.B., Spiegelman D., Willett W.C., and Rimm E.B. Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. Am. J. Epidemiol. 159 (2004 Jun 15) 1150-1159
36. Kotchen T.A., Zhang H.Y., Reddy S.R., and Hoffman R.G. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am. J. Physiol. 270 (1996) R660-R666
37. Law R.E., Xi X.P., and Hseuh W.A. Troglitazone inhibits insulin, EGF, and PDGF mitogenic signal transduction in A10 vascular smooth muscle and mesangial cells. Hypertension 26 (1995) 553 (Abstract)
38. Lee M.K., Miles D.G., Khoursheed M., Gao K.M., Moossa A.R., and Olefsky J.M. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 43 (1994) 1435-1439
39. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270 (1995) 12953-12956
40. Licata G., Volpe M., Scaglione R., and Rubattu S. Salt-regulating hormones in young normotensive obese subjects. Effects of saline load. Hypertension 23 (1994) I20-I124
41. Lihn A.S., Pedersen S.B., and Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes. Rev. 6 (2005) 13-21
42. Makino A., Skelton M.M., Zou A.P., Roman R.J., and Cowley Jr. A.W. Increased renal medullary oxidative stress produces hypertension. Hypertension 39 (2002) 667-672
43. McVeigh G.E., and Cohn J.N. Endothelial dysfunction and the metabolic syndrome. Curr. Diab. Rep. 3 (2003) 87-92
44. Modan M., Halkins H., Almog S., et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J. Clin. Invest. 26 (1985) 809
45. Nakamura T., Funahashi T., Yamashita S., Nishida M., Nishida Y., Takahashi M., Hotta K., Kuriyama H., Kihara S., Ohuchi N., Nishimura T., Kishino B.I., Ishikawa K., Kawamoto T., Tokunaga K., Nakagawa C., Mineo I., Watanabe F., Tarui S., and Matsuzawa Y. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diabetes Res. Clin. Pract. (2001) 54181-54190
46. Negro R., Dazzi D., Hassan H., and Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol. 29 (2004) 11-17
47. Nishimoto Y., Tomida T., Matsui H., Ito T., and Okumura K. Decrease in renal medullary endothelial nitric oxide synthase of fructose-fed, salt-sensitive hypertensive rats. Hypertension 40 (2002) 190
48. Nolan J.J., Ludvik B., Beerdsen P., et al. Improvements in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331 (1994) 1188-1193
49. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., and Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
50. Ogihara T., Rakugi H., Ikegami H., Mikami H., and Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. 8 (1995) 316-320
51. Oliver Jr. W.R., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., and Willson T.M. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5306-5311
52. Ortiz P.A., and Garvin J.L. Interaction of O2- and NO in the thick ascending limb. Hypertension 39 (2002) 591-596
53. Poirier P., Lemieux I., Mauriège P., Dewailly E., Blanchet C., Bergeron J., and Després J.-P. Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension 45 (2005) 363-367
54. Postnov Y.V., and Orlov S.N. Ion transport across plasma membranes in primary hypertension. Physiol. Rev. 65 (1985) 904-945
55. Raji A., Seely E.W., Bekins S.A., Williams G.H., and Simonson D.C. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26 (2003) 172-178
56. Rowley K., O'Dea K., and Best J.D. Association of albuminuria and the metabolic syndrome. Curr. Diab. Rep. 3 (2003) 80-86
57. Ryan M.J., Didion S.P., Mathur S., Faraci F.M., and Sigmund C.D. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 (2004) 661-666
58. Saku K., Zhang B., Ohta T., and Arakawa K. Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits. Am. J. Hypertens. 10 (1997) 1027-1033
59. Saltiel A.R., and Olefsky J.M. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 45 (1996) 1661-1669
60. Sawicki P.T., Heinemann L., Starke A., and Berger M. Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia 35 (1992) 649-652
61. Schoonjans K., Martin G., Staels B., and Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8 (1997) 159-166
62. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., and Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
63. St-Pierre P., Bouffard L., and Maheux P. Rosiglitazone increases extravasation of macromolecules and endothelial nitric oxide synthase in skeletal muscles of the fructose-fed rat model. Biochem. Pharmacol. 67 (2004) 1997-2004
64. Sung B.H., Izzo J., Dandona P., and Wilson M.F. Vasodilatory effects of troglitazone improve blood pressure at rest and during menal stress in type 2 diabetes mellitus. Hypertension 34 (1999) 83-88
65. Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Ganz P., and Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97 (1996) 22-28
66. Trimarco B., Volpe M., Ricciardelli B., Picotti G.B., Galva M.D., Petracca R., and Condorelli M. Studies of the mechanisms underlying impairment of beta-adrenoceptor-mediated effects in human hypertension. Hypertension 5 (1983) 584-590
67. Tsunoda S., Kamide K., Minami J., and Kawano Y. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. Am. J. Hypertens. 15 (2002) 697-701
68. Tugwood J.D., Issemann I., Anderson R.G., Bundell K.R., McPheat W.L., and Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 11 (1992) 433-439
69. Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., and Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J. Biol. Chem. 273 (1998) 31108-31112
70. Wakino S., Law R.E., and Hsueh W.A. Vascular protective effects by activation of nuclear receptor PPARgamma. J Diabetes its Complicat. 16 (2002) 46-49
71. Walker A.B., Chattington P.D., Buckingham R.E., and Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48 (1999) 1448-1453
72. Widlansky M.E., Sesso H.D., Rexrode K.M., Manson J.E., and Gaziano J.M. Body mass index and total and cardiovascular mortality in men with a history of cardiovascular disease. Arch. Intern. Med. 22 164 (2004) 2326-2333
73. Williams B. Glucose-induced vascular smooth muscle dysfunction: the role of protein kinase C. J. Hypertens. 13 (1995) 477-486
74. Wyszynski D.F., Waterworth D.M., Barter P.J., Cohen J., Kesaniemi Y.A., Mahley R.W., McPherson R., Waeber G., Bersot T.P., Sharma S.S., Nolan V., Middleton L.T., Sundseth S.S., Farrer L.A., Mooser V., and Grundy S.M. Relation between atherogenic dyslipidemia and the adult treatment program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic SyndromeProject). Am. J. Cardiol. 15 (2005) 194-198
75. Yoshimoto T., Naruse M., Shizume H., Naruse K., Tanabe A., Tanaka M., Tago K., Irie K., Muraki T., Demura H., and Zardi L. Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 145 (1999) 33340
76. Yoshioka S., Nishino H., Shiraki T., Ikeda K., Koike H., Okuno A., Wada M., Fujiwara T., and Horikoshi H. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42 (1993) 75-80
77. Zhang H.Y., Reddy S., and Kotchen T.A. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension 24 (1994) 106-110
78. Zhang F., Sowers J.R., Ram J.L., Standley P.R., and Peuler J.D. Effects of pioglitazone in calcium channels in vascular smooth muscle. Hypertension 24 (1994) 170-175